BioMarin Pharmaceutical Acquires Zystor Therapeutics for $115,000,000
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=55f39173-fd7d-4d4e-bb40-e1f8f7dc457b&Preview=1 -
Date
8/17/2010 -
Company Name
Zystor Therapeutics -
Mailing Address
10437 Innovation Drive Milwaukee, WI 53226-4838 -
Company Description
ZyStor Therapeutics, Inc. is a biotechnology company developing innovative therapeutics that will significantly improve the lives of patients who suffer from genetic disorders known as lysosomal storage diseases (LSDs. -
Website
http://www.zystor.com -
Transaction Type
M&A -
Transaction Amount
$115,000,000 -
Transaction Round
-
Proceeds Purposes
-
M&A Terms
Under the terms of the agreement, BioMarin acquired ZyStor for $22 million upfront and up to an additional $93 million if certain development, regulatory and commercial milestones are achieved.
